Microbiology Nuts & Bolts
  • Home
  • Basic Concepts
    • What is infection?
    • Normal flora
    • Diagnosing infection
  • Microbiology
    • Basic bacterial identification
    • Interpreting bacteriology results
    • Interpreting serology results
  • Infection Control
    • What is infection control?
    • Universal precautions
    • MRSA
    • Clostridium difficile
  • Clinical Scenarios
    • Respiratory infections
    • Urinary infections
    • GI infections >
      • D&V
      • CDAD
    • CNS infections
    • Skin & bone infections
    • Sepsis
  • Antibiotics
    • Antimicrobial Stewardship
    • How antibiotics work
    • How to choose an antibiotic?
    • Reviewing antibiotics
    • Antibiotic resistance
    • Testing antibiotic resistance
    • Penicillin allergy
    • Theraputic Drug Monitoring
  • Guidelines
  • Lectures & Lecture Notes
    • Medical Students
    • Curriculum for the Foundation Program
    • Foundation Year 1
    • Foundation Year 2
    • Other Lectures
  • The Bug Blog
  • Buy the book...
  • NEW Edition Updates
  • Peer Reviews
  • Our Facebook page
  • Want to know more?
  • Contact

Carbapenemases - the “Big Five”

19/3/2014

 
carbapenemases structure
I have recently had the pleasure of interviewing for new Consultant colleagues and I thought it would be good to ask them “what infection  keeps you awake at night?” Their answers where all the same: carbapenemases.

So what are carbapenemases and why are they
worrying?

A carbapenemase is a mechanism of resistance used by bacteria to defend themselves against carbapenem antibiotics.
• They are Beta-lactamase enzymes.
• They tend to give resistance to ALL of the Beta-lactam antibiotics such as the penicillins and cephalosporins.
• They mainly occur in Gram-negative bacilli, which tend to cause more episodes of sepsis.
• They are often associated with other resistance mechanisms, giving resistance to other antibiotics such as the quinolones (e.g. Ciprofloxacin) and aminoglycosides (e.g. Gentamicin).
• They cause resistance to carbapenem antibiotics, (Ertapenem, Meropenem, Imipenem and Doripenem) which are often the last line in the fight against Gram-negative infections. Clinically they are therefore very difficult to treat; patients with infections with carbapenemase-producing bacteria have a very high mortality, in excess of 50%. They are true “Superbugs” and keep microbiologists awake at night! 

The carbapenemases can be split into 2 broad categories, the reason the categories are important is for infection control purposes: 
•  Intrinsic
Intrinsic carbapenemases occur inherently in the bacterium but are not transferrable between bacterial species and can only be spread by spreading the bacteria e.g. poor hand hygiene. They occur in bacteria with a low potential to cause infection and cannot be transferred into bacteria with a high potential to cause infection. They have been present in the UK for many years.
•  Acquired
Acquired Carbapenemases are relatively new worldwide. Resistance occurs because the bacterium has gained the ability to become resistant (usually via the acquisition of a plasmid containing the genes encoding the carbapenemase). It is more worrying than intrinsic resistance because it can be spread by passing on the plasmid to other bacterial species which can cause severe infections e.g. E. coli, K.
pneumoniae.
Intrinsic and Acquired Carbapenemases
Click for larger image
There are five main carbapenemases currently causing clinical problems; affectionately known as the “Big Five”:
• KPC (Klebsiella pneumoniae carbapenemase)
• IMP (Imipenemase metallo-beta-lactamase)
• NDM (New Delhi metallo-beta-lactamase)
• VIM (Verona integron-encoded metallo-beta-lactamase)
• OXA (Oxacillin carbapenemases)

They can be split into 3 main groups based on the similarity
enzymes.
Carbapenemases Enzymes.
Click for larger image
Current Global Spread of Carbapenemase Resistance (http://wwwnc.cdc.gov/eid/)
Global Spread of Carbapenemase Resistance KPC
Click for larger image
Global Spread of Carbapenemase Resistance VIM & IMP
Click for larger image
Global Spread of Carbapenemase Resistance NDM
Click for larger image
Global Spread of Carbapenemase Resistance OXA-48
Click for larger image
Treatment
Carbapenemase-producing bacteria cause infections just as
readily as their non-resistant counterparts. However, the normal first and second line antibiotics used in UK hospitals are unlikely to be effective and the mortality to these infections may be in excess of 50%. If these bacteria are
identified treatment options are limited and the antibiotics often have side-effects and complications (see the book, "Microbiology Nuts & Bolts").

Most carbapenemase-producing bacteria remain sensitive to:
•  Polymyxins e.g. Colistin
•  Tigecycline
•  Nitrofurantoin
•  Fosfomycin

The current recommendations for severe infections caused by carbapenemase-producing bacteria are combinations of
antibiotics:
•  Colistin PLUS carbapenem
•  OR Colistin PLUS Tigecycline
•  OR Colistin PLUS aminoglycoside

What does the future hold?
So should my Consultant colleagues be really worrying about
carbapenemases? YES! Are we entering a post-antibiotic era? PROBABLY! What should we be doing to detect and prevent the spread of carbapenemases? How do we preserve the limited active antibiotics we have remaining and how do we manage patients with carbapenemase-producing bacteria from an infection control point of view? GOSH...I’d better blog on that next week, as I’m already late to bed. Don't have nightmares!
Peter English link
17/4/2014 08:06:49 am

This is just what I needed - thanks, David!


Comments are closed.

    RSS Feed

    Blog Author:

    David Garner
    Consultant Microbiologist
    Surrey, UK

    Please DO NOT advertise products and conferences on our website or blog

    Categories

    All
    Antibiotic Resistance
    Antibiotics
    Basic Concepts
    Clinical Scenarios
    Guidelines
    Infection Control
    In The News
    Microbiology

    Archives

    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    October 2013
    September 2013
    August 2013
    July 2013

    Categories

    All
    Antibiotic Resistance
    Antibiotics
    Basic Concepts
    Clinical Scenarios
    Guidelines
    Infection Control
    In The News
    Microbiology

    RSS Feed

Powered by Create your own unique website with customizable templates.